Evaluation of Gingival Crevicular Fluid Cytokine Profiles in Children and Young Adults With Gingivitis

ConditionGingivitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age8-24
SponsorNigde Omer Halisdemir University

About this trial

This prospective observational case-control study aims to compare gingival crevicular fluid (GCF) biomarker profiles between children and young adults diagnosed with gingivitis. A total of approximately 80 systemically healthy participants will be recruited and divided into two groups: children aged 8-12 years and young adults aged 15-24 years. Individuals aged 13-14 years will be excluded as they represent a transitional pubertal period characterized by significant hormonal fluctuations that may influence inflammatory responses and confound biomarker levels.

Clinical periodontal parameters including gingival index, plaque index, bleeding on probing, and probing depth will be recorded. In addition, GCF samples will be collected from a standardized tooth and analyzed for levels of IL-1β, TNF-α, IL-10, and MMP-8 using enzyme-linked immunosorbent assay (ELISA).

The primary objective of the study is to evaluate and compare inflammatory and anti-inflammatory cytokine profiles between the two age groups. The findings may contribute to understanding age-related differences in gingival inflammatory responses and the potential role of hormonal transition in periodontal disease expression during childhood and early adulthood.

Eligibility criteria

Qualifiers

Individuals aged 8-12 years (child group) or 15-24 years (young adult group)

Clinical diagnosis of gingivitis

Presence of fully erupted tooth #31 with closed apex

Systemically healthy individuals

Disqualifiers

Age 13-14 years (transitional pubertal period)

Presence of periodontitis or other periodontal diseases

Systemic, genetic, or immunological diseases

Acute oral infections or conditions requiring emergency treatment

Trial design

Treatments tested in this trial

  • Gingival Crevicular Fluid Biomarker Assessment

Treatment groups

80 Participants
are divided into 2 treatment groups